Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

YOU WONT BELIEVE: 8 - You Need To See This

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

Zenger

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Barchart

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Barchart

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Kiplinger

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Barchart

Read news from The Economist, FT, and more,
with one subscription

How Fortune 500 companies are supporting employees amid financial instability

Financial wellness benefits have become popular as employers focus on retention.

Fortune

Reskilling and financial well-being top HR’s talent strategy list amid economic downturn

Fortune 500 HR execs share how they’re recession-proofing their talent strategy. Hint: Financial wellness benefits and reskilling.

Fortune

Federal government to penalize AbbVie over the price of its blockbuster drug Humira

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday.

Chicago Tribune

3 Income Stocks to Buy Now if You're Starving for Cash

The Fed will likely keep raising interest rates to bring inflation down to its desired level. This is expected to keep the stock market and the economy under pressure this year. Amid the uncertainty, investors looking for passive income could add fundamentally strong dividend-paying stocks AbbVie (ABBV), Valero Energy (VLO),…

StockNews.com

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

WEKU

Ignore the ‘superpower’ boasts – UK pharma looks superchallenged

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

The Guardian - UK

The #1 Pharma Stock to Buy in January 2023

While the stock market and the economy have been subdued by progressive interest-rate increases, AbbVie Inc. (ABBV) has not only reported a robust third quarter but also demonstrated its confidence in its long-term prospects by raising its quarterly dividend. Read on….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Warren Buffett Stocks to Buy and Never Sell

Legendary investor Warren Buffett’s holding company Berkshire Hathaway has outperformed the broader market over the past year. His investment portfolio has been a guide for several long-term investors for decades. Amid a highly uncertain market and economic backdrop, Warren Buffett holdings Procter & Gamble (PG), AbbVie (ABBV), Biogen (BIIB), and…

The Conversation

I'm thinking of surgery for endometriosis. What's involved? Does it work?

Endometriosis is a painful condition caused by the presence of tissue similar to the lining of the uterus found outside the uterus. It affects around one in nine women and people assigned female at birth.

StockNews.com

1 No-Brainer Stock to Buy That Could Help You Retire Earlier

Biopharma giant AbbVie (ABBV) is well-placed to gain from its drug pipeline, recent drug approvals, and strategic acquisitions. Given its strong fundamentals, discounted valuation, high profitability, reliable dividends, and favorable analyst estimates, investing in this stock could help you retire earlier. Read more.

Benzinga

AbbVie Unusual Options Activity For October 28

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 13 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Tesla's Autopilot Draws Regulatory Scrutiny, Volkswagen Expects Supply Crisis To Continue, TikTok To Launch Standalone Gaming Channel: Top Stories Friday, Oct. 28

Wall Street Journal Tesla’s Autopilot Draws Regulatory Ire From DoJ and SEC

Benzinga

Congresswoman's Spouse Purchases 2 Dividend Stocks, Sells Amazon And Comcast Shares

Democratic Congresswoman Kathy Manning has filed over 450 trades in the past three years, according to Capitol Trades.

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 13 strange trades.

Benzinga

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On AbbVie

Benzinga

What Are Whales Doing With AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Benzinga

Looking At AbbVie's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

1 … 7 8 9 10

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.